High Evidence
Research Overview
Survodutide Research for MASH/NAFLD
An evidence-based overview of research examining Survodutide in the context of mash/nafld. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2 RCT (N=293) showed up to 62% MASH improvement without worsening of fibrosis vs 14% placebo, and up to 36% fibrosis improvement (>=1 stage) vs 22% placebo at 48 weeks. A >=30% reduction in liver fat occurred in 57-67% of survodutide groups vs 14% placebo. Phase 3 development is ongoing.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.